NewLimit

About:

NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.

Twitter/X: newlimit

Top Investors: Elad Gil, Founders Fund, Kleiner Perkins, Garry Tan, Dimension

Description:

NewLimit specializes in treating age-related diseases to extend the human health span. It works on developing epigenetic reprogramming medicines to treat diseases with large unmet needs.

Total Funding Amount:

$40M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2022-01-01

Founders:

Blake Byers, Brian Armstrong, Greg Johnson, Jacob Kimmel

Number of Employees:

11-50

Last Funding Date:

2023-05-16

IPO Status:

Private

Industries: